Skip to content
Clinical Trials – home

Diacerein: A Comprehensive Guide for Patients

1 / 1
trials open to patients / all trials
8+
Countries

In short

Diacerein is a medication that has been the subject of several clinical trials, investigating its effectiveness in treating various medical conditions. These trials have primarily focused on its use in osteoarthritis, particularly of the knee and hip, as well as its potential benefits in other areas such as ocular surface disease and type 2 diabetes. Researchers have been exploring diacerein's anti-inflammatory properties and its ability to inhibit interleukin-1, a key factor in the progression of certain diseases.

At a glance

Primary Conditions Studied
Osteoarthritis (knee, hip, hand), Ocular Surface Disease, Type 2 Diabetes
Mechanism of Action
Anti-inflammatory, Interleukin-1 inhibitor
Common Dosages
50 mg once or twice daily, often with dose escalation
Key Outcome Measures
Pain reduction, Joint space measurement, Glycemic control, Inflammatory markers
Study Designs
Randomized controlled trials, Bioequivalence studies, Observational studies
Duration of Studies
Ranging from 2 months to 3 years
Unique Applications
Ocular surface disease in arthritis, Metabolic control in diabetes
Safety Considerations
Long-term use in elderly patients, Liver function monitoring

What is Diacerein?

Diacerein is a medication primarily used to treat osteoarthritis, a common joint condition that causes pain and stiffness. It belongs to a class of drugs known as anthraquinones and has anti-inflammatory properties. Diacerein is also known by several other names, including Artrodar, Artifit, and Acert.

Conditions Treated with Diacerein

Diacerein is primarily used to treat the following conditions:

  • Osteoarthritis: This is the main condition for which diacerein is prescribed. It's particularly used for osteoarthritis of the knee and hip.
  • Hand Osteoarthritis: Some studies have investigated the use of diacerein for osteoarthritis affecting the hands.
  • Ocular Surface Disease: Research is being conducted to evaluate diacerein's effectiveness in treating dry eye conditions in patients with degenerative arthritis.

How Diacerein Works

Diacerein works differently from typical pain relievers. Its main mechanism of action involves:

  • Interleukin-1 (IL-1) Inhibition: Diacerein inhibits a protein called interleukin-1 beta (IL-1β), which plays a fundamental role in osteoarthritis and cartilage destruction.
  • Anti-inflammatory Effects: By inhibiting IL-1β, diacerein helps reduce inflammation in the joints.
  • Cartilage Protection: Unlike some pain medications that may accelerate cartilage degeneration, diacerein may help slow down the progression of joint damage.

Dosage and Administration

The typical dosage and administration of diacerein may vary depending on the specific condition and the prescriber's instructions. However, based on the clinical trials reviewed:

  • The usual starting dose is 50 mg once daily, often taken with meals.
  • After an initial period (often 2-4 weeks), the dose may be increased to 50 mg twice daily.
  • Diacerein is typically available in capsule or tablet form.

Always follow your doctor's instructions regarding dosage and administration.

Effectiveness of Diacerein

Several studies have investigated the effectiveness of diacerein:

  • Pain Relief: Diacerein has shown analgesic (pain-relieving) efficacy comparable to diclofenac, a commonly used pain medication, in patients with knee osteoarthritis.
  • Joint Space Preservation: A long-term study (ECHODIAH) evaluated diacerein's ability to slow the decrease in joint space width in hip osteoarthritis patients.
  • Symptom Improvement: Studies have used various measures such as the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score and visual analog scale (VAS) for pain to assess diacerein's effectiveness in improving osteoarthritis symptoms.

Potential Side Effects

While diacerein is generally well-tolerated, it may cause some side effects. The most commonly reported side effect is:

  • Gastrointestinal Issues: Some patients may experience digestive system effects. Studies have specifically monitored for gastrointestinal side effects.

Always discuss potential side effects with your healthcare provider.

Ongoing Research and Future Potential

Researchers are exploring additional uses for diacerein beyond osteoarthritis treatment:

  • Diabetes Management: Studies are investigating diacerein's potential to improve glycemic control in patients with type 2 diabetes.
  • Non-alcoholic Fatty Liver Disease: Research is examining whether diacerein can help reduce liver fat in patients with type 2 diabetes.
  • Ocular Surface Disease: A study is evaluating diacerein's effectiveness in treating dry eye conditions.

These ongoing studies may reveal new potential uses for diacerein in the future, expanding its therapeutic applications beyond osteoarthritis treatment.

Questions people often ask

Conditions where Diacerein is being studied

Each condition opens its own overview and trial list

Trials with Diacerein

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).